At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 120 enrolled
Drug / intervention
triptorelin embonate (INN)drug
Likely dose
triptorelin embonate (INN) 22.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics and Safety of Two Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer.
In Brief
A Phase 3 clinical trial evaluating triptorelin embonate (INN) for Prostatic Neoplasm. Completed, enrolled 120 participants across 1 site.
Detailed Summary
Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. It was assumed that during the study treatment \>90% of the patients would achieve and maintain castrate levels of serum testosterone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasm
CountriesSouth Africa
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
Primary CompletionAug 2007
First PostedSep 2008
TodayJul 2026
First PostedSep 12, 2008
Enrollment StartJul 1, 2006
Primary CompletionAug 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.8 years ago
Interventions
triptorelin embonate (INN)drug
Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks